Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 869-883 , October 2008

Bone-forming agents in the management of osteoporosis

  • Jean-Yves Reginster, MD, PhD (Full Professor and Chairman)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +32 4 270 32 57; Fax: +32 4 270 32 53.

References 

  1. Reginster J, Rizzoli Y. Ostéoporose postménopausique. Traitement prophylactique. Paris: Masson; 1993;
  2. Riggs BL, Khosla , Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. Journal of Bone and Mineral Research. 1998;13:763–773
  3. Christiansen C, Lindsay R. Estrogens, bone loss and preservation. Osteoporosis International. 1991;1:714
  4. Reginster JY, Denis D, Albert A, et al. 1-year controlled randomised trial of prevention of early postmenopausal bone loss with intranasal calcitonin. Lancet. 1987;2:1481–1483
  5. Reginster JY, Jupsin I, Deroisy R, et al. Prevention of postmenopausal bone loss by rectal calcitonin. Calcified Tissue International. 1995;56:539–542
  6. Hosking DJ, McKlung MR, Ravn , et al. Alendronate in the prevention of osteoporosis: EPIC study two-year results. Journal of Bone and Mineral Research. 1996;11:133
  7. Mortensen L, Bekker P, Ouweland PVD, et al. Prevention of early postmenopausal bone loss by risedronate: a two-year study. Journal of Bone and Mineral Research. 1995;10:140
  8. Reginster JY, Lecart MP, Deroisy R, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989;2:1469–1471
  9. Reginster JY. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner. 1993;23:223–232
  10. Reginster JY, Deroisy R, Lecart MP, et al. Prévention de l'ostéoporose à Liège: le PIGEPS dix ans plus tard. Santé Publique. 1996;2:139–150
  11. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541
  12. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. HipIntervention Program Study Group. The New England Journal of Medicine. 2001;344:333–340
  13. Reginster JY, Minne HW, Sorensen OH, et al. Randomized trial of the effect of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International. 2000;11:83–91
  14. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. The Journal of Clinical Endocrinology and Metabolism. 2002;87:3609–3617
  15. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA : The Journal of the American Medical Association. 1999;282:1344–1352
  16. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International. 2004;15:792–798
  17. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases. 2006;65:654–661
  18. Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clinical Rheumatology. 2008;[Epub ahead of print]
  19. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. The Journal of Rheumatology. 2008;35(3):488–497
  20. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. The New England Journal of Medicine. 2007;357:1799–1809
  21. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine. 2007;356:1809–1822
  22. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodelling and bone structure. Journal of Bone and Mineral Research. 2008;23:6–16
  23. Reginster JY, Taquet AN, Fraikin G, et al. Parathyroid hormone in the treatment of involutional osteoporosis: back to the future. Osteoporosis International. 1997;7:S163–S167
  24. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England Journal of Medicine. 2001;344:1434–1441
  25. Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research. 2003;18:18–23
  26. Lindsay R, Scheels WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1–34)) in postmenopausal women with osteoporosis. Archives of Internal Medicine. 2004;164:2024–2030
  27. Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. Journal of Bone and Mineral Research. 2005;20:1507–1513
  28. Delmas PD, Licata AA, Reginster JY, et al. Fracture Risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover. Bone. 2006;39:237–243
  29. Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. The Journal of Clinical Investigation. 1999;104:371–373
  30. Greenspan SL, Bone HG, Ettinger MP, et al. Treatment of Osteoporosis with Parathyroid Hormone Study Group. Annals of Internal Medicine. 2007;146:326–339
  31. Shrader SP, Raggucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. The Annals of Pharmacotherapy. 2005;39:1511–1516
  32. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone (1-84) in increasing bone mineral density in postmenopausal osteoporosis. The Journal of Clinical Endocrinology and Metabolism. 2003;88:5212–5220
  33. Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine Reviews. 2005;26:688–703
  34. Reginster JY, Deroisy R, Dougados M, et al. Prevention of early postmenopausal bone loss by strontium ranelate: a randomized, two-year, double-blind, dose-ranging, placebo-controlled trial. Osteoporosis International. 2002;13:925–931
  35. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis: a 2-year randomized placebo controlled trial. The Journal of Clinical Endocrinology and Metabolismolism. 2002;87:2060–2066
  36. Reginster JY, Diez-Perez A, Ortolani S, et al. Calcium-vitamin D supplementation in clinical trials of osteoporosis should be titrated on the basis of pre-study assessments. Osteoporosis International. 2002;13:S24
  37. Reginster JY, Spector T, Badurski J, et al. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate Phase III program. Osteoporosis International. 2002;13:S30
  38. Meunier PJ, Roux C, Ortolani S, et al. Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporosis International. 2002;13:O45
  39. Meunier PJ, Roux C, Seeman E, et al. The effect of strontium ranelate on the risk of vertebral fracture in Women with Post Menopausal Osteoporosis. The New England Journal of Medicine. 2004;350:459–468
  40. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2816–2822
  41. Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. Journal of Bone and Mineral Research. 2006;21:536–542
  42. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. Journal of Bone and Mineral Research. 2006;21:1113–1120
  43. Seeman E, Devogelaer J, Lorenc R, et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Journal of Bone and Mineral Research. 2007 Nov 12;[Epub ahead of print]
  44. Reginster JY, Meunier PJ. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Osteoporosis International. 2003;14:S56–S65
  45. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. The Journal of Clinical Endocrinology and Metabolism. 2007;92:3076–3081
  46. Bruyere O, Roux C, Badurski J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Current Medical Research and Opinion. 2007;23:3041–3045
  47. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and μ-CT Analysis of Bone Biopsies from Postmenopausal Osteoporotic Women Treated with Strontium Ranelate. Journal of Bone and Mineral Research. 2008;23:215–222
  48. Shea B, Wells G, Cranney A, et al., Osteoporosis Methodology Group , Osteoporosis Research Advisory Group  Calcium supplementation on bone loss in postmenopausal women. Cochranese of Systematic Reviews. 2004;1:CD004526
  49. Question and answers on the safety of PROTELOS/OSSEOR. Doc. Ref. EMEA/534613/2007 www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/Protelos_Q&;A_53461307en.pdf-2007-11-16
  50. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology. 2003;206:353–356
  51. Frost HM. Treatment of osteoporosis by manipulation of coherent bone cell populations. Clinical Orthopaedics and Related Research. 1979;143:227–244
  52. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550–555
  53. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. Journal of Bone and Mineral Research. 2001;16:925–931
  54. Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. The Journal of Clinical Investigation. 1998;102:1627–1633
  55. Lane NE, Sanchez S, Modin GW, et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. Journal of Bone and Mineral Research. 2000;15:944–951
  56. Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. Journal of Bone and Mineral Research. 2004;19:745–750
  57. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. The New England Journal of Medicine. 2003;349:1207–1215
  58. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. The New England Journal of Medicine. 2003;349:1216–1226
  59. Khosla S. Parathyroid hormone plus alendronate – A combination that does not add up. The New England Journal of Medicine. 2003;349:1277–1279
  60. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2129–2134
  61. Rhee Y, Won YY, Baek MH, et al. Maintenance of increased bone mass after recombinant human parathyroid hormone (1-84) with sequential zoledronate treatment in ovariectomized rats. Journal of Bone and Mineral Research. 2004;19:931–937

PII: S1521-690X(08)00078-X

doi: 10.1016/j.beem.2008.06.003

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 869-883 , October 2008

Article Tools

* Image Usage & Resolution